Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07721467 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Recruitment opened Start date: Oct 13, 2026 to Oct 14, 2026 · Eligibility criteria shortened, about 1,982 words Show 2 more changesShow less
    • Start date: Oct 13, 2026 to Oct 14, 2026
    • Eligibility criteria shortened, about 1,982 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting Start date: Oct 12, 2026 to Oct 13, 2026 · Site details revised · Eligibility criteria shortened, about 3 words Show 3 more changesShow less
    • Start date: Oct 12, 2026 to Oct 13, 2026
    • Site details revised
    • Eligibility criteria shortened, about 3 words
  3. Minor Start date: Oct 11, 2026 to Oct 12, 2026 Eligibility criteria expanded, about 3 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 3 words
  4. Minor Start date: Oct 8, 2026 to Oct 11, 2026
  5. Minor Start date: Oct 7, 2026 to Oct 8, 2026
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Start date: Oct 6, 2026 to Oct 7, 2026
  2. Minor Start date: Oct 5, 2026 to Oct 6, 2026
  3. Minor Start date: Oct 4, 2026 to Oct 5, 2026
  4. Minor Start date: Oct 1, 2026 to Oct 4, 2026 Eligibility criteria shortened, about 16 words · Study description expanded, about 17 words Show 2 more changesShow less
    • Eligibility criteria shortened, about 16 words
    • Study description expanded, about 17 words
  5. Minor Re-verified, no change to tracked fieldsv3
  6. Minor Study title shortened, about 7 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking. Researchers want to know if regular mental tasks (cognitive training) can improve brain function in older adults. They also want to know if psilocybin, a compound found in certain mushrooms, can further support improved brain function. Objective: To learn how regular cognitive training, with or without psilocybin, can improve brain health in older adults. Eligibility: People aged 65 years and older with mild cognitive impairment or early-stage Alzheimer s disease. Healthy older adults with normal cognition are also needed. Design: Participants will be screened. They will have a test of their heart function and an imaging scan. They will have mental health screening and tests of their thinking and memory. They will practice brain-training tasks on a tablet. Participants will be divided into 2 groups: 1 will have cognitive training plus psilocybin; 1 will have cognitive training only. Those having cognitive training only will have 5 or 6 clinic visits. They will take the tablet home to practice brain training daily. They will wear a device to measure brain waves as they sleep; they may have 1 overnight stay in the clinic, or they may wear the device at home. Imaging scans and other tests will be repeated at each visit. Those taking psilocybin will have up to 9 clinic visits. In addition to the visits for cognitive training, they will take 1 psilocybin capsule by mouth 2 weeks apart (the second dose is optional). They will remain in the clinic for 24 hours after each dose.
Trial Details
NCT Number NCT07721467
Lead Sponsor National Institute on Aging (NIA)
Conditions Alzheimer's Disease
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov